



# Platelet mitochondrial cytochrome c oxidase subunit I variants with benzene poisoning

Dianpeng Wang<sup>1</sup>, Xiangli Yang<sup>1</sup>, Yanfang Zhang<sup>1</sup>, Dafeng Lin<sup>1</sup>, Paimao Li<sup>1</sup>, Zhiming Zhang<sup>1</sup>, Xianqing Huang<sup>1</sup>, Dayong Gu<sup>2</sup>, Jacky Fong-Chuen Loo<sup>3</sup>

<sup>1</sup>Shenzhen Prevention and Treatment Center for Occupational Diseases, Shenzhen 518020, China; <sup>2</sup>Shenzhen International Travel Health Care Center and Shenzhen Academy of Inspection and Quarantine, Shenzhen 518033, China; <sup>3</sup>Department of Biomedical Engineering, The Chinese University of Hong Kong, Hong Kong, China

**Contributions:** (I) Conception and design: D Wang; (II) Administrative support: Y Zhang, X Huang; (III) Provision of study materials or patients: X Yang, Z Zhang; (IV) Collection and assembly of data: P Li; (V) Data analysis and interpretation: D Lin, D Gu, JF Loo; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Yanfang Zhang, MD. Shenzhen Prevention and Treatment Center for Occupational Diseases, 2019 Buxin Rd., Luohu District, Shenzhen 518020, China. Email: 13923431511@139.com; Jacky Fong-Chuen Loo, PhD. Department of Biomedical Engineering, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Email: jackyfcloo@cuhk.edu.hk.

**Background:** Chronic benzene poisoning (CBP) is one of the most common chronic occupational poisoning which is associated with mitochondrial oxidative damage, and lead to increasing risk of respiratory diseases such as lung cancer. Cytochrome c oxidase subunit I (COI) is one of the key enzymes that plays an important role in oxidative damage regulation by eliminating reactive oxygen species (ROS). This study investigated the relationship between COI gene variants and the risk of CBP.

**Methods:** We investigated 44 non-smoking patients who were diagnosed with CBP and 57 unexposed non-smoking controls between the ages of 23 and 60 with their background including work experience, lifestyle and medical records. Peripheral blood (2 mL) was collected in EDTA tube and the platelet was purified from the collected blood. Variants of COI were analyzed by PCR and sequencing. Multivariable linear regression analysis was used to assess the association between CBP exposure and variants.

**Results:** The frequency of the mitochondrial DNA (mtDNA) T6392C, G6962 variants were 10, 7 out of 44 CBP group patients, which was higher when compared to that of 4, 2 out of 57 in the control group, suggesting these variants could be the risk factor for CBP [odds ratio (OR) 3.897, 95% CI: 1.131–13.425, P=0.023; OR 5.203, 95% CI: 1.024–26.442, P=0.034]. There was a significant difference (P<0.05) of COI variants, including T6392C and G6962A, in platelet mtDNA between patients and control samples. Meanwhile, the frequency of the mtDNA C7196A variant were 13 out of 44 control group, which was higher when compared to that of 2 of 57 in the CBP group patients, suggesting this variant could be the protective factor for CBP (OR 6.205, 95% CI: 1.320–29.162, P=0.010).

**Conclusions:** Our study suggests that T6392C, G6962A and C7196A from platelet mtDNA variants play a significant role in the etiology of CBP and facilitate the development of molecular biomarker on CBP diagnosis.

**Keywords:** Chronic benzene poisoning (CBP); mitochondrial DNA (mtDNA) variants; cytochrome c oxidase subunit I (COI); platelet mtDNA

Submitted Jul 25, 2018. Accepted for publication Nov 05, 2018.

doi: 10.21037/jtd.2018.11.82

View this article at: <http://dx.doi.org/10.21037/jtd.2018.11.82>

## Introduction

Chronic benzene poisoning (CBP), caused by frequent occupational exposure to benzene such as by breathing in, is one of the most common chronic occupational poisoning, according to the annual report of occupational diseases in China (1). The severity of CBP varies from white blood cell (WBC) decrease to lung cancer and leukemia. The risk of developing CBP can be affected by genetic variants, when engaging in benzene exposing work (2,3). Reactive oxygen species (ROS) production in response to benzene metabolite hydroquinone in bone marrow has caused oxidative DNA damage (4). In the past few decades, molecular genetics of the CBP has been focusing on the changes in genomic DNA. Pathogenic nuclear and mitochondrial variants associated to CBP have been identified by different laboratories (5-7). Multiple susceptibility loci in the pathogenesis among groups of CBP have been investigated, some linkage scans and candidate gene studied have been suggested have roles in CBP (8,9).

The major mechanism on the impairment of bone marrow by benzene and its metabolized products is through mitochondrial oxidative damage (10). Mitochondria have the key functions in maintaining living stage through energy metabolism, and self-death program execution through apoptosis (11). Energy metabolism generates ROS, the free radical causing oxidative damage in mitochondrial DNA (mtDNA), which affects the encoding of metabolic enzymes (12). It eventually leads to variants in mitochondrial genome, and mitochondrial dysfunctions that are related to diseases and clinically heterogeneous group of disorders, ranging from single-organ to severe multisystemic damage, such as lung cancer, leukemia, heart failure, Leber's hereditary optic neuropathy, and Leigh's syndrome (10,13-17). Human cytochrome c oxidase subunit I (COI), encoded by the mtDNA as the catalytic core of the cytochrome c oxidase, transfers electrons from reduced cytochrome c to molecular oxygen, and contributes to maintaining the electrochemical gradient across the inner mitochondrial membrane (18). COI plays an important role in the metabolism of benzene, as it operates as a ROS scavenger and is a part of cellular and mitochondrial defense mechanism against oxidative stress (19).

Circulating blood platelet contains fully functional mitochondria. The abundance of platelets in human blood circulation and the ease of collection by syringe have made this an attractive source of mitochondria for investigating mitochondrial dysfunction related to human diseases. Since

platelets do not contain a nucleus, mtDNA characterization will not be interfered from chromosomal DNA (20). T6392C and T6962A sites of COI gene showed a low variant frequency in the European population in Cambridge Human Mitochondrial Database (21). However, there is a lack of investigation of COI gene in the Asian population. Therefore, in this study, we investigated whether these two COI variants, as well as other potential variants, from platelet mitochondria could be associated with the occurrence of CBP in Chinese population in Asia. It would provide insights into variant frequency of COI gene in different populations for future researches on poisoning by benzene and its relative analogues.

## Methods

### *Collection of blood samples*

A total of 44 CBP patients and 57 healthy persons were recruited from several major factories in Shenzhen, China as our cases and controls with agreement. Written informed consent was obtained from all patients and volunteers before sample and data collection. Benzene poisoning diagnosed from 2010 to 2016 by local authorized Occupational Disease Diagnostic Team has included (I) total WBC counts <4,000  $\mu\text{L}$  or WBC counts between 4,000 and 4,500  $\mu\text{L}$  and platelet counts <80,000  $\mu\text{L}$ , with repeated confirmation of these counts after a few months in a peripheral blood examination; (II) documented benzene exposure as a result of employment in the factory for at least 6 months; and (III) the exclusion of other known causes of abnormal blood counts, such as chloromycetin use and ionizing radiation. The medical records of these patients were independently reviewed by at least two hemopathologists, particularly those with WBC counts >3,500 to confirm the CBP diagnosis. The diagnostic criteria for occupational CBP are provided by the Ministry of Health and Family Planning Committee. Diagnostic criteria for severe CBP is defined on the basis of chronic poisoning with at least one of the following manifestations, complete cytopenia, aplastic anemia, myelodysplastic syndrome and leukemia, while that for mild CBP is defined on the basis of a long history of close contact with benzene, associated with symptoms such as dizziness, headache, fatigue, insomnia, memory loss or infection. The cases and controls donated 2 mL of venous blood and their demographic data were recorded. The subjects were administered a rigorous physical examination in Shenzhen Occupational Disease Hospital.

**Table 1** Basic profile of the patients and control group

Profile	Patient (n=44)	Control (n=57)	Test	P
Age (years)	40.3±6.5	37.7±9.8	-1.588 <sup>a</sup>	0.163
Sex (male: female)	12:32	23:34	1.876 <sup>b</sup>	0.116
WBC counts	3.2±0.4	6.3±1.7	-12.511 <sup>a</sup>	0.000
Platelet counts	189.2±58.4	241.4±56.8	-4.517 <sup>a</sup>	0.000
Poisoning period (severe: mild)	9:35	0		

<sup>a</sup>, *t*-test; <sup>b</sup>, Chi-square test ( $\chi^2$ ). WBC, white blood cell.

Ethical approval of the study was granted by the Ethics Committee of Shenzhen Prevention and Treatment Center for Occupational Diseases.

### Platelet and DNA extraction

Peripheral blood (2 mL) was collected in EDTA tubes. The bloods were centrifuged at 100 g for 15 min immediately, and the supernatant was platelet. Nucleic acids were extracted from the platelet by extraction kit (Sangon DNA Mini Kit), according to the manufacturer's instruction. DNA quantity was assessed by the spectrometer (NanoDrop). The measured DNA was stored at -80 °C until analysis.

### Analysis of COI variants

Genotyping for COI variants was performed by polymerase chain reaction (PCR) in an applied biosystems step-one-plus PCR instrument. PCR was performed in a total of 40 µL volume containing 20 µL of 2× PrimeSTAR HS (Premix) (Takara), 1 µL of each primer (10 pmol; Sangon Biotechnology) (forward: 5'-CACTTAGTAAACAGCTAAGCACCC-3'; reverse: 5'-GGGCGTGATCATGAAAGGTG-3'), 16 µL of H<sub>2</sub>O and 2 µL DNA. A three-step PCR cycle for COI was performed. The initial denaturation at 95 °C for 1 min was followed by 15 cycles of denaturation at 95 °C for 10 s, annealing at 58 °C for 30 s, extension at 72 °C for 120 s, and a final that followed by 25 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, extension at 72 °C for 120 s. Each amplified fragment was certified and purified using Agarose Gel DNA Fragment Recovery Kit (Sangon Biotechnology) and subsequently sequenced using an ABI PRISM 3730 sequence analyzer (Sangon

Biotechnology), according to the manufacturer's instruction. The sequences obtained were aligned with a multiple sequence's alignment interface CLUSTAL-X to compare with standard mitochondrial sequence. Identified variations were confirmed by repeated analysis of both standard mitochondrial sequence and mitochondrial database.

### Statistical analysis

Statistical analysis was conducted to determine the odds ratios (ORs) of Pearson Chi-square. The frequencies of each group in cases and controls were compared with Pearson  $\chi^2$ /Fisher's exact test. WBC, platelet (PLT) and age of each group in cases and controls were compared with *t*-test. A *P* value less than 0.05 was considered significant. All analyses were performed with SPSS software version 16.0.

## Results

### Subject characteristics

A total of 101 participants were recruited as our cases and controls in this study. *Table 1* summarized the basic profile of patients and controls, and *Table 2* described the detail profile of the individuals. There was no difference in age and gender distribution between the cases and controls, suggesting there is no genetic bias in subjects for age and gender (*Tables 1,2*). Meanwhile, there were a significant difference in WBC and PLT distribution between the cases and controls (*Table 1*).

*Table 3* showed the comparison of WBC/PLT between severe and mild CBP patients. There was no difference in age and PLT distribution between severe and mild CBP within the diagnostic threshold, while there was a significant difference in WBC distribution between severe and mild CBP (*Table 3*).

**Table 2** Clinical characteristics of individual CBP patients

Patient ID	Age (years)	Sex	WBC	Diagnosis
1	47	Female	3.4	CBP (severe)
2	50	Female	3.3	CBP (mild)
3	37	Female	3.7	CBP (mild)
4	47	Male	3.3	CBP (mild)
5	45	Female	3.3	CBP (mild)
6	43	Male	2.7	CBP (mild)
7	35	Male	2.3	CBP (mild)
8	38	Female	3.3	CBP (mild)
9	47	Female	3.7	CBP (mild)
10	37	Male	3.8	CBP (severe)
11	35	Female	2.7	CBP (mild)
12	43	Female	3.5	CBP (mild)
13	40	Female	2.8	CBP (mild)
14	39	Female	3.3	CBP (mild)
15	41	Female	3.8	CBP (mild)
16	51	Female	3.5	CBP (severe)
17	28	Male	3.7	CBP (mild)
18	26	Female	3.3	CBP (severe)
19	50	Female	3.2	CBP (severe)
20	36	Female	2.8	CBP (mild)
21	44	Female	3.1	CBP (mild)
22	35	Female	3.2	CBP (severe)
23	42	Female	3.2	CBP (mild)
24	32	Male	2.8	CBP (mild)
25	41	Male	2.9	CBP (mild)
26	40	Male	3.5	CBP (mild)
27	44	Female	3.0	CBP (mild)
28	39	Female	3.0	CBP (mild)
29	30	Male	3.3	CBP (mild)
30	46	Female	3.0	CBP (mild)
31	41	Female	3.2	CBP (mild)
32	45	Female	3.4	CBP (mild)
33	36	Female	3.8	CBP (mild)
34	27	Male	3.9	CBP (severe)
35	49	Female	3.0	CBP (mild)

**Table 2** (continued)**Table 2** (continued)

Patient ID	Age (years)	Sex	WBC	Diagnosis
36	46	Female	2.9	CBP (mild)
37	43	Female	2.9	CBP (mild)
38	38	Male	3.7	CBP (severe)
39	52	Female	3.1	CBP (mild)
40	46	Female	3.8	CBP (mild)
41	35	Male	3.3	CBP (mild)
42	29	Female	2.2	CBP (mild)
43	38	Female	3.3	CBP (severe)
44	41	Female	3.2	CBP (mild)

CBP, chronic benzene poisoning; WBC, white blood cell.

**Table 3** WBC and PLT of the severe and mild CBP

Profile	Severe (n=9)	Mild (n=35)	t	P
Age (years)	40.7±5.8	38.7±9.1	-0.782	0.439
WBC (10 <sup>9</sup> /L)	3.2±0.3	3.5±0.2	2.283	0.028
PLT (10 <sup>9</sup> /L)	193.9±58.1	164.4±60.7	-1.347	0.185

WBC, white blood cell; PLT, platelet; CBP, chronic benzene poisoning.

### *Analysis of the platelet mtDNA variant profile*

The COI variant was assessed in all subjects. In total, 9 and 33 variant sites were shown in the controls and cases respectively. The cases showed 4 frame shifts (frmsht) and 3 missense variant sites. The T6392C variant was found in 14 subjects: 10 in CBP cases and 4 in the control subjects. The G6962A variant was found in 9 subjects: 7 in CBP cases and 2 in the control subjects. C7196A variant was found in 15 subjects: 2 in CBP cases and 13 in the control subjects. There was a significant difference in the frequency of the T6392C, G6962A and C7196A variants (*Table 4*).

### *Analysis of the correlation between variants and benzene poisoning*

There was no difference in benzene poisoning parameters, WBC and PLT, between the wild and the variant of the cases and controls (*Tables 5,6*). Genotype differences do not affect WBC and platelet baseline levels and diagnostic thresholds.

**Table 4** Summary of the analysis of mitochondrial COI DNA variants.

Variants	Type	Residue change	Control (n=57)	Case (n=44)	OR (95% CI)	P
T5948C	Transition	I ≥ I	0	1	1.023 (0.978–1.070)	0.253
T5964C	Transition	L ≥ L	0	1	1.023 (0.978–1.070)	0.253
G5985A	Transition	V ≥ I	0	1	1.023 (0.978–1.070)	0.253
T6092C	Transition	F ≥ F	0	1	1.023 (0.978–1.070)	0.253
A6125G	Transition	M ≥ M	0	1	1.023 (0.978–1.070)	0.253
G6179A	Transition	M ≥ M	2	2	1.310 (0.177–9.683)	0.791
T6253C	Transition	M ≥ T	0	1	1.023 (0.978–1.070)	0.253
G6267A	Transition	A ≥ T	1	1	1.279 (0.078–21.042)	0.863
A6353d	Deletion	frmshtft	0	1	1.023 (0.978–1.070)	0.253
G6366A	Transition	V ≥ V	1	2	0.651 (0.057–7.420)	0.728
T6392C	Transition	N ≥ N	4	10	3.897 (1.131–13.425)	0.023*
C6424CC	Insertion	frmshtft	0	1	1.023 (0.978–1.070)	0.253
C6455T	Transition	F ≥ F	7	8	1.587 (0.528–4.774)	0.408
C6482T	Transition	V ≥ V	0	1	1.023 (0.978–1.070)	0.253
C6531T	Transition	L ≥ L	0	1	1.023 (0.978–1.070)	0.253
T6626G	Transversion	P ≥ P	0	1	1.023 (0.978–1.070)	0.253
A6647C	Transversion	L ≥ L	0	1	1.023 (0.978–1.070)	0.253
T6680C	Transition	T ≥ T	4	6	2.092 (0.552–7.926)	0.269
T6681C	Transition	Y ≥ H	0	1	1.023 (0.978–1.070)	0.253
C6689CC	Insertion	frmshtft	0	1	1.023 (0.978–1.070)	0.253
T6707C	Transition	F ≥ F	0	1	1.023 (0.978–1.070)	0.253
G6709GG	Insertion	frmshtft	0	1	1.023 (0.978–1.070)	0.253
T6782C	Transition	F ≥ F	0	1	1.023 (0.978–1.070)	0.253
C6797T	Transition	D ≥ D	0	1	1.023 (0.978–1.070)	0.253
C6960T	Transition	L ≥ L	0	2	1.048 (0.982–1.117)	0.187
G6962A	Transition	L ≥ L	2	7	5.203 (1.024–26.442)	0.034*
C7028T	Transition	A ≥ A	41	34	1.327 (0.533–3.301)	0.543
T7040C	Transition	Y ≥ Y	0	1	1.023 (0.978–1.070)	0.253
C7160T	Transition	I ≥ I	0	1	1.023 (0.978–1.070)	0.253
C7196A	Transversion	L ≥ L	13	2	6.205 (1.320–29.162)	0.010*
A7250G	Transition	T ≥ T	0	1	1.023 (0.978–1.070)	0.253
C7280A	Transversion	F ≥ L	0	1	1.023 (0.978–1.070)	0.253

\*, P&lt;0.05. COI, cytochrome c oxidase subunit I; OR, odds ratio; CI, confidence interval; frmshtft, frame shifts.

**Table 5** WBC and PLT of the controls with the variant

Variants	WBC (10 <sup>9</sup> /L)	PLT (10 <sup>9</sup> /L)	t <sup>w</sup>	P <sup>w</sup>	t <sup>p</sup>	P <sup>p</sup>
T6392T (n=53)	6.3±1.8	241.0±58.3	-0.848	0.400	-0.016	0.987
T6392C (n=4)	5.6±0.7	241.0±36.6				
G6962G (n=55)	6.3±1.7	240.4±57.6	-0.997	0.323	0.695	0.490
G6962A (n=2)	5.1±0.74	269.0±9.8				
C7196C (n=55)	6.4±1.8	242.3±5.3	0.679	0.5	0.279	0.782
C7196A (n=2)	5.9±1.1	236.5±7.5				

<sup>w</sup>, WBC *t*-test; <sup>p</sup>, platelet *t*-test. WBC, white blood cell; PLT, platelet.

**Table 6** WBC and PLT of the CBP cases with the variant

Genotype	WBC (10 <sup>9</sup> /L)	PLT (10 <sup>9</sup> /L)	t <sup>w</sup>	P <sup>w</sup>	t <sup>p</sup>	P <sup>p</sup>
T6392T	3.3±0.4	193.7±64.2	0.043	0.966	-1.212	0.232
T6392C	3.2±0.3	168.1±31.9				
G6962G	3.2±0.4	193.9±61.5	0.423	0.674	-1.226	0.227
G6962A	3.3±0.4	164.5±29.8				
C7196C	3.3±0.4	188.6±59.8	-0.219	0.828	-0.386	0.702
C7196A	3.2±0.3	172.0±56.5				

<sup>w</sup>, WBC *t*-test; <sup>p</sup>, platelet *t*-test. WBC, white blood cell; PLT, platelet; CBP, chronic benzene poisoning.

## Discussion

In the present study, we investigated platelet mtDNA and screened the COI gene of CBP and healthy individual. The number of COI variants was greater in cases [33] than in controls [9]. These variant changes might affect the expression level of the COI protein with the other subunits as the location and the type of this variants could affect the transfer of electrons from reduced cytochrome *c* to molecular oxygen (22). These variants may play a role in oxidation damage by increasing the production ROS production during mitochondrial oxidative phosphorylation. The resultant ROS are mitogenic, and may result in increased sensitivity to benzene metabolism products, which in turn leads to toxicity and increased risk of CBP (23). Indeed, high ROS release from respiratory chain is known to reduce synthesis of the blood cells (24). Besides, the mutation in COI gene, impairing the transcription of corresponding mRNA, reduces the overall activity of the COI for respiratory regulation in mitochondria, thus results in low ATP synthesis for energy supply (25). A total of 95% of energy supply from ATP is provided by mitochondria, and the ATP is required for blood cell synthesis (26)

Therefore, high ROS level or reduction in ATP synthesis in mitochondria due to CBP will lead to lower blood cells level of an individual. The above phenomenon is matched with the clinical diagnostic markers, which are the reduction in WBC and PLT, in patients with mild or severe CBP. Lower WBC count is found in severe CBP than that of mild CBP implying the immune defensive system is impaired strongly with severe CBP.

In addition, we identified 4 COI frame shift variants in our study that were not reported previously. T6392C and G6962A of our findings distributed differently in the COI gene, which was previously reported in the Human Mitochondrial Database (<http://www.mitomap.org>). The T6392C and G6962A has been studied in various populations, none of which has shown a significant association with disease, even though the mutation was identified in all tested population (27). Although we did not find a significant association between the presence of one or more COI missense variants and CBP, our study provides insight for further study as there has been a lack of examination of variants in COI gene and the association between the variants and CBP from previous literatures.

Meanwhile, C7196A variant may have protective mutation effect, as certain alleles of mtDNA in certain halo-groups with protective or deleterious roles have been reported (13). Besides, repetitive and insertion and deletion mtDNA sequences associated with the benzene poisoning in Chinese population in Asia did not occur in this study. Indeed, some typical mtDNA variants, such as Mt4738C and Mt4738A have been found with a lower ROS production that could act against ROS associated conditions in mice (28). Further investigation of the mechanism *in vivo*, as well as human epidemiological studies on these mtDNA variants, will be beneficial to the understanding of the relationship between different variants and benzene poisoning. Nevertheless, further research will help to seek out the potential significance of the T6392C, G6962A and C7196A mutations in Asian Chinese CBP.

### Conclusions

In this study, two platelet mtDNA variants, i.e., T6392C and G6962A, in COI gene are related to the CBP in Asian Chinese individuals, which has not been reported from Western individuals. Additionally, C7196A variant was found in Chinese individuals, and it might have protective mutation effect. These three mtDNA variants could be potentially used as the biomarker to facilitate the molecular detection to identify CBP or other occupational contraindications.

### Acknowledgements

**Funding:** This work was supported by Medical Scientific Research Foundation of Guangdong Province (A2018165), Science and Technology Program of Shenzhen (JCYJ20160429090813380), the National Natural Science Foundation of China (No. 81502797). We thank all the volunteers who have participated in this study. We thank Huiming Liu from Hebei Northern Medical College for helping with the samples collection and processing.

### Footnote

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** Written informed consent was obtained from all patients and volunteers before sample and data collection. Ethical approval of the study was granted by the

Ethics Committee of Shenzhen Prevention and Treatment Center for Occupational Diseases (ID: 2017116104245249).

### References

1. Tang XZ, Zeng Q, Liu DS. A cost-benefit analysis of occupational disease reporting in China. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 2017;35:226-9.
2. Sun P, Zhang Z, Wu F, et al. Association of the genetic polymorphism of EPHX1 and EPHX2 with the susceptibility to chronic benzene poisoning. *Front Med China* 2007;1:320-6.
3. Wan JX, Zhang ZB, Guan JR, et al. Genetic polymorphism of toxicant-metabolizing enzymes and prognosis of Chinese workers with chronic benzene poisoning. *Ann N Y Acad Sci* 2006;1076:129-36.
4. Bratton SB, Lau SS, Monks TJ. Identification of quinol thioethers in bone marrow of hydroquinone/phenol-treated rats and mice and their potential role in benzene-mediated hematotoxicity. *Chem Res Toxicol* 1997;10:859-65.
5. Liu Y, Chen X, Bian Q, et al. Analysis of plasma microRNA expression profiles in a Chinese population occupationally exposed to benzene and in a population with chronic benzene poisoning. *J Thorac Dis* 2016;8:403-14.
6. Xiao S, Gao L, Liu Y, et al. Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population. *Mutat Res* 2013;751:52-8.
7. Xue P, Gao L, Xiao S, et al. Genetic Polymorphisms in XRCC1, CD3EAP, PPP1R13L, XPB, XPC, and XPF and the Risk of Chronic Benzene Poisoning in a Chinese Occupational Population. *PLoS One* 2015;10:e0144458.
8. Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. *Cancer Res* 1997;57:2839-42.
9. Nakayama A, Noguchi Y, Mori T, et al. Comparison of mutagenic potentials and mutation spectra of benzene metabolites using supF shuttle vectors in human cells. *Mutagenesis* 2004;19:91-7.
10. Kodroń A, Ghanim M, Krawczyk KK, et al. Mitochondrial DNA in pediatric leukemia patients. *Acta Biochim Pol* 2017;64:183-7.
11. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance

- drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. *J Biol Chem* 2003;278:37832-9.
12. Sanchez-Roman I, Gomez A, Gomez J, et al. Forty percent methionine restriction lowers DNA methylation, complex I ROS generation, and oxidative damage to mtDNA and mitochondrial proteins in rat heart. *J Bioenerg Biomembr* 2011;43:699-708.
  13. Kumar M, Kaur P, Kumar M, et al. Clinical characterization and mitochondrial DNA sequence variations in Leber hereditary optic neuropathy. *Mol Vis* 2012;18:2687-99.
  14. Wang K, Takahashi Y, Gao ZL, et al. Mitochondrial ND3 as the novel causative gene for Leber hereditary optic neuropathy and dystonia. *Neurogenetics* 2009;10:337-45.
  15. Järviaho T, Hurme-Niiranen A, Soini HK, et al. Novel non-neutral mitochondrial DNA mutations found in childhood acute lymphoblastic leukemia. *Clin Genet* 2018;93:275-85.
  16. Zhou J, Gou H, Ye Y, et al. Sequence variations of mitochondrial DNA D-loop region in patients with acute myeloid leukemia. *Oncol Lett* 2017;14:6269-76.
  17. Veerapandiyam A, Chaudhari A, Traba CM, et al. Novel mutation in mitochondrial DNA in 2 siblings with Leigh syndrome. *Neurol Genet* 2016;2:e99.
  18. Müller M, Azzi A. Subunit I is the catalytic center of *Paracoccus denitrificans* cytochrome c oxidase. *Ann N Y Acad Sci* 1988;550:13-21.
  19. Atlante A, Calissano P, Bobba A, et al. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. *J Biol Chem* 2000;275:37159-66.
  20. Schapira AH, Marsden CD. Platelet mitochondrial DNA in Parkinson's disease. *Mov Disord* 1994;9:119-21.
  21. Lott MT, Leipzig JN, Derbeneva O, et al. mtDNA Variation and Analysis Using Mitomap and Mitomaster. *Curr Protoc Bioinformatics* 2013;44:1.23.1-26.
  22. Baklouti-Gargouri S, Ghorbel M, Chamkha I, et al. Possible association of a novel missense mutation A6375G in the mitochondrial cytochrome C oxidase I gene with asthenospermia in the Tunisian population. *Genet Test Mol Biomarkers* 2012;16:1298-302.
  23. Li Z, Khaletskiy A, Wang J, et al. Genes regulated in human breast cancer cells overexpressing manganese-containing superoxide dismutase. *Free Radic Biol Med* 2001;30:260-7.
  24. Delhaye J, Salamin N, Roulin A, et al. Interspecific correlation between red blood cell mitochondrial ROS production, cardiolipin content and longevity in birds. *Age (Dordr)* 2016;38:433-43.
  25. Furui T, Kurauchi O, Tanaka M, et al. Decrease in cytochrome C oxidase and cytochrome oxidase subunit I messenger RNA levels in preeclamptic pregnancies. *Obstet Gynecol* 1994;84:283-8.
  26. Figura M, Chilton L, Liacini A, et al. Blockade of K(ATP) channels reduces endothelial hyperpolarization and leukocyte recruitment upon reperfusion after hypoxia. *Am J Transplant* 2009;9:687-96.
  27. Gusdon AM, Votyakova TV, Mathews CE. mt-Nd2a suppresses reactive oxygen species production by mitochondrial complexes I and III. *J Biol Chem* 2008;283:10690-7.
  28. Honmyo R, Kokaze A, Karita K, et al. Influence of mitochondrial DNA 5178 C/A polymorphism on serum cholesterol changes: a short-term follow-up in middle-aged Japanese men. *Environ Health Prev Med* 2012;17:401-7.

**Cite this article as:** Wang D, Yang X, Zhang Y, Lin D, Li P, Zhang Z, Huang X, Gu D, Loo JF. Platelet mitochondrial cytochrome c oxidase subunit I variants with benzene poisoning. *J Thorac Dis* 2018;10(12):6811-6818. doi: 10.21037/jtd.2018.11.82